Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
Proteolytic targeting chimaeras (PROTACs) have been developed as an effective technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of interest (POIs) by recruiting the ubiquitin-proteasome system, thereby inhibiting...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2022.2074414 |
| _version_ | 1818215483146502144 |
|---|---|
| author | Chao Wang Yujing Zhang Lingyu Shi Shanbo Yang Jing Chang Yingjie Zhong Qian Li Dongming Xing |
| author_facet | Chao Wang Yujing Zhang Lingyu Shi Shanbo Yang Jing Chang Yingjie Zhong Qian Li Dongming Xing |
| author_sort | Chao Wang |
| collection | DOAJ |
| description | Proteolytic targeting chimaeras (PROTACs) have been developed as an effective technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of interest (POIs) by recruiting the ubiquitin-proteasome system, thereby inhibiting the intracellular level of POIs. To date, a variety of small-molecule PROTACs (CRBN, VHL, IAP, and MDM2-based PROTACs) have been developed. IAP-based PROTACs, also known as specific and nongenetic IAP-dependent protein erasers (SNIPERs), are used to degrade the target proteins closely related to diseases. Their structures consist of three parts, including target protein ligand, E3 ligase ligand, and the linker between them. So far, many SNIPERs have been extensively studied worldwide and have performed well in multiple diseases, especially cancer. In this review, we will present the most relevant advances in the field of SNIPERs and provide our perspective on the opportunities and challenges for SNIPERs to become therapeutic agents. |
| first_indexed | 2024-12-12T06:36:47Z |
| format | Article |
| id | doaj.art-1bb81f185be94960847f7174c8cefb8e |
| institution | Directory Open Access Journal |
| issn | 1475-6366 1475-6374 |
| language | English |
| last_indexed | 2024-12-12T06:36:47Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Enzyme Inhibition and Medicinal Chemistry |
| spelling | doaj.art-1bb81f185be94960847f7174c8cefb8e2022-12-22T00:34:27ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742022-12-013711437145310.1080/14756366.2022.2074414Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agentsChao Wang0Yujing Zhang1Lingyu Shi2Shanbo Yang3Jing Chang4Yingjie Zhong5Qian Li6Dongming Xing7The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaProteolytic targeting chimaeras (PROTACs) have been developed as an effective technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of interest (POIs) by recruiting the ubiquitin-proteasome system, thereby inhibiting the intracellular level of POIs. To date, a variety of small-molecule PROTACs (CRBN, VHL, IAP, and MDM2-based PROTACs) have been developed. IAP-based PROTACs, also known as specific and nongenetic IAP-dependent protein erasers (SNIPERs), are used to degrade the target proteins closely related to diseases. Their structures consist of three parts, including target protein ligand, E3 ligase ligand, and the linker between them. So far, many SNIPERs have been extensively studied worldwide and have performed well in multiple diseases, especially cancer. In this review, we will present the most relevant advances in the field of SNIPERs and provide our perspective on the opportunities and challenges for SNIPERs to become therapeutic agents.https://www.tandfonline.com/doi/10.1080/14756366.2022.2074414PROTACsIAPSNIPERsdegradationpromising treatment |
| spellingShingle | Chao Wang Yujing Zhang Lingyu Shi Shanbo Yang Jing Chang Yingjie Zhong Qian Li Dongming Xing Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents Journal of Enzyme Inhibition and Medicinal Chemistry PROTACs IAP SNIPERs degradation promising treatment |
| title | Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents |
| title_full | Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents |
| title_fullStr | Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents |
| title_full_unstemmed | Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents |
| title_short | Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents |
| title_sort | recent advances in iap based protacs snipers as potential therapeutic agents |
| topic | PROTACs IAP SNIPERs degradation promising treatment |
| url | https://www.tandfonline.com/doi/10.1080/14756366.2022.2074414 |
| work_keys_str_mv | AT chaowang recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT yujingzhang recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT lingyushi recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT shanboyang recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT jingchang recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT yingjiezhong recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT qianli recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents AT dongmingxing recentadvancesiniapbasedprotacssnipersaspotentialtherapeuticagents |